Research Areas

A Historical-Controlled, Multicenter, Double-Blind, Randomized Trial to Assess the Efficacy and Safety of Conversion to An Investigational Medication 400mg/day Monotherapy in Subjects with Partial-onset Seizures

A randomized, double-blind, placebo-controlled, multi-center, 24-week study to evaluate the safety and tolerability of an investigational medication in patients with diabetic nephropathy associated with type 1 or type 2 diabetes.

Clinical Evaluation of An Investigational Continuous Glucose Monitoring System

A Phase II, Open-Label, Dose Exposure Confirmation Study to Evaluate the Pharmacokinetics and Safety and Tolerability of An Investigational Medication in Adult Patients with Non-Valvular Atrial Fibrillation or Atrial Flutter

12 Week Treatment With an Investigational Medication Versus Placebo in Patients With Asthma

A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of An Investigational Oral Medication in Type 1 Diabetic Patients With Diabetes-Associated Nephropathy

Combination therapy of Metformin with Once-Daily Evening Dose of An Investigational Insulin or Human Insulin NPH: Comparison of Safety and Efficacy in Subjects with Type 2 Diabetes Previously Inadequately Controlled with Monotherapy or Oral Combination Therapy with Metformin – A Randomized, Six-Month, Open Label, Parallel Design Multicenter Trial

A Double-Blind, Randomized Study to Evaluate the Effect of An investigational Medication in Subjects With Type 2 diabetes Mellitus Who Have Inadequate Glycemic Control On Half-Maximum to Maximum of the Labeled Doses of Sulfonylurea Monotherapy

A 12-Week, Double Blind, Randomized, Placebo-Controlled, Multicenter Study of An Investigational Medication on Glucose Control In Patients with Type 2 Diabetes Mellitus Not Optimally Controlled on a Sulfonylurea

Repaglinide vs. Nateglinide in Combination with Metformin: Comparative Efficacy and Safety: An Open Label, Randomized, Parallel Group, Multi-Center Study In the Treatment of Patients With Type 2 Diabetes Inadequately Controlled with Sulfonylurea or Metformin Monotherapy or Low-Dose Glucovance

A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study of an Investigational Medication in Type 2 Diabetic Patients

Double-Blind, Randomized, Parallel Group Clinical Trial to Compare the Efficacy, Safety, and Tolerability of An Investigation Medication and Metformin Immediate Release Tablets in the Treatment of Type 2 Diabetes Mellitus

A Multicenter, Double-Blind, Randomized, Placebo- and Active-Controlled, Parallel Study to Evaluate the Glucose and Lipid-altering Efficacy and Safety of an Investigational Oral Medication in Patients with Type 2 Diabetes.

Multicenter, Randomized, Double-blind, Active Controlled trial to Compare the Efficacy and Safety of 104 weeks of Nateglinide plus Metformin vs. Glyburide plus Metformin in Drug Naïve Subjects with Type 2 Diabetes Mellitus Who have Inadequate Glycemic Control with Diet and Exercise.

Evaluation of Diabetic Retinopathy Progression in Subjects with Type 2 Diabetes Mellitus Treated with Insulin.

26 Week, Multinational, Multicenter, Controlled, Open, 1:1 Randomized, Parallel Clinical Trial Comparing Investigational Insulin with Regular Human Insulin Injected Subcutaneously in Subjects With Type2 Diabetes Mellitus also Using NPH Insulin, and Which Will Lead into a Comparative 26 – Week Safety Extension Study.

A Randomized, Double-Blind, Active-Controlled Parallel Group Efficacy and Safety Study of an Investigational Medication (5.0 mg Administered Orally Once Daily) Compared to Glimperiride ( 1 to 4 mg once daily) Over Two Years, in Type 2 Diabetic Patients with Insufficient Glycaemic Control Despite Metformin Therapy

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter 12-Week Study Assessing the Efficacy and Safety of an Investigational Medication in Drug Naive Patients with Type 2 Diabetes

A Phase IIa, Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy and Safety of an Investigational Medication in Combination with Sitagliptin or in Combination with Metformin in Patients with Type 2 Diabetes Mellitus who Have Inadequate Glycemic Control

A Phase 2A, Randomized, Double-Blind, Comparator and Placebo Controlled, Multiple Dose Study to Evaluate the Safety, Tolerability and Efficacy of Two Dose Levels of An Investigational Medication in Type 2 Diabetic Patients